Is Noevir Holdings profitable in 2026?

Yes, Noevir Holdings posted net income attributable to owners of approximately ¥8.03-8.2 billion for fiscal year 2025 (ended Sep 30, 2025), on ¥64.72 billion in sales, though Q1 FY2026 operating income fell 29.0% year-on-year as of results reported Feb 5, 2026.

Is Noevir Holdings losing to Pola Orbis?

Pola Orbis is roughly 2.5 times Noevir's scale, with FY2024 consolidated net sales of about ¥165 billion versus Noevir's ¥64.72 billion in FY2025, and Pola Orbis's ORBIS direct-selling channel is showing double-digit growth while Noevir's Q1 FY2026 sales fell 7.9%.

Could AI replace Noevir Holdings' beauty consultants?

Unlikely soon: Noevir's core model is person-to-person direct sales through roughly 2,000 Noevir Beauty Studios, a relationship-based counseling workflow that AI diagnostics tools do not directly replace, though rivals KOSE and Shiseido shipped AI skin-diagnostics in 2025 while Noevir showed no public AI rollout as of November 2025.

Is Noevir Holdings cutting jobs?

Headcount is slowly shrinking rather than being cut sharply: Noevir employed 1,263 people as of September 30, 2025, down from 1,369 the prior year, a decline of 15 employees (-1.10%), consistent with a mature, low-growth organization.

Who owns Noevir Holdings?

Noevir Holdings is an independent, publicly traded company on the Tokyo Stock Exchange Prime Market (ticker 4928) with no parent conglomerate; Japan's Government Pension Investment Fund held about 3.93% of shares as of March 2023, per fund disclosures.

Is Noevir Holdings a safe company to join in 2026?

It is a stable, dividend-paying 60-plus-year-old cosmetics group planning a ¥230 per share dividend for FY2026, but Q1 FY2026 results (reported Feb 5, 2026) showed sales down 7.9% and operating income down 29% year-on-year, raising questions about whether full-year guidance of ¥65.0 billion sales will be met.

Consumer brands · Japan

Noevir Holdings Co., Ltd.

noevirholdings.co.jp ↗

Japanese direct-sales cosmetics maker selling skincare through door-to-door consultants.

Defensible for now

Assessed 26 July 2026 · Evidence as of 26 July 2026

Real protection, with named pressure against it.

On the recordSince 26 July 2026 · Checkable from May 2026 · Every call on the record Checkpoint: H1 FY2026 earnings release, testing whether Q1's sales and profit drop was a blip or a trend

The call

A profitable, dividend-paying company with a slowing core business, no visible AI push, and a larger rival growing faster in its own channel.

Noevir sells skincare and cosmetics mainly through independent sales consultants who build personal customer relationships, which is hard to replicate quickly. However, bigger rival Pola Orbis is growing much faster in the same sales channel, and competitors like Kosé and Shiseido have launched AI skin-scanning tools that Noevir has not yet matched, suggesting the company's old way of doing things may no longer be enough. The biggest signal to watch is whether Noevir can keep paying its dividend as planned and whether sales stop shrinking in the next few quarterly reports, since a dividend cut would mean the company itself believes the advantage is fading.

Why

AI pressure: KOSE and Shiseido AI skin-diagnostic tools. Rivals now offer AI skin scanners that mimic what a Noevir consultant does in person, with no phone visit needed. Could AI do the core job? Unlikely.

Bigger players: Pola Orbis Holdings. Pola Orbis runs the same direct-sales model at 2.5x Noevir's size and keeps growing double digits while Noevir stalls. Could a giant copy it? Probably.

What protects it. Quasi-drug regulatory approvals and decades-long consultant relationships that are slow for outsiders to copy.

What would change this call

Noevir H1 FY2026 results (expected May 2026) versus ¥65B/¥11.4B full-year guidance. Shows whether Q1's decline was a blip or the start of sustained erosion.
Noevir FY2026 dividend announcement versus planned ¥230/share. A cut would signal the consultant/distribution moat is weakening financially.
Whether Noevir ships AI skin-diagnostic tools to Beauty Studios within 12 months of its Nov 2025 CTO hire. Tests if it can match KOSÉ and Shiseido's 2025 AI diagnostics rollout.

Key numbers

Q1 FY2026 sales fell 7.9% YoY to ¥15.466B (2026-02-05)
FY2025 net sales ¥64.72B, up just 1.4% YoY (2025-11-07)
FY2026 guidance: ¥65.0B sales, ¥11.4B op income (2025-11-07)

Named risks

Q1 FY2026 sales down 7.9% and operating income down 29% may signal start of sustained decline. Severity: high
FY2026 guidance of ¥65.0B sales, ¥11.4B operating income at risk of being missed. Severity: medium
No visible AI diagnostics rollout while KOSE and Shiseido shipped tools in 2025. Severity: medium
Slow headcount decline (-1.10% YoY as of Sep 2025) reflecting mature, low-growth organization. Severity: low
Dividend cut possible if earnings weakness from Q1 FY2026 persists into H1/Q3. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Pola Orbis Holdings	losing to	2.5x Noevir's scale (~¥165B vs ¥64.72B FY2025) with double-digit ORBIS direct-sales growth
KOSE Corporation	losing to	Shipped AI skin-diagnostics in 2025 vs Noevir's no visible AI capability as of Nov 2025
Shiseido	contesting	Shiseido market cap ~¥1.1T (2026-06-07) also shipped AI diagnostics in 2025, dwarfing Noevir in scale
Chinese C-beauty brands	losing to	Industry report (2025-11-18) flags structural erosion of Japanese incumbents from C-beauty entrants

Questions people ask

Is Noevir Holdings profitable in 2026?: Yes, Noevir Holdings posted net income attributable to owners of approximately ¥8.03-8.2 billion for fiscal year 2025 (ended Sep 30, 2025), on ¥64.72 billion in sales, though Q1 FY2026 operating income fell 29.0% year-on-year as of results reported Feb 5, 2026.
Is Noevir Holdings losing to Pola Orbis?: Pola Orbis is roughly 2.5 times Noevir's scale, with FY2024 consolidated net sales of about ¥165 billion versus Noevir's ¥64.72 billion in FY2025, and Pola Orbis's ORBIS direct-selling channel is showing double-digit growth while Noevir's Q1 FY2026 sales fell 7.9%.
Could AI replace Noevir Holdings' beauty consultants?: Unlikely soon: Noevir's core model is person-to-person direct sales through roughly 2,000 Noevir Beauty Studios, a relationship-based counseling workflow that AI diagnostics tools do not directly replace, though rivals KOSE and Shiseido shipped AI skin-diagnostics in 2025 while Noevir showed no public AI rollout as of November 2025.
Is Noevir Holdings cutting jobs?: Headcount is slowly shrinking rather than being cut sharply: Noevir employed 1,263 people as of September 30, 2025, down from 1,369 the prior year, a decline of 15 employees (-1.10%), consistent with a mature, low-growth organization.
Who owns Noevir Holdings?: Noevir Holdings is an independent, publicly traded company on the Tokyo Stock Exchange Prime Market (ticker 4928) with no parent conglomerate; Japan's Government Pension Investment Fund held about 3.93% of shares as of March 2023, per fund disclosures.
Is Noevir Holdings a safe company to join in 2026?: It is a stable, dividend-paying 60-plus-year-old cosmetics group planning a ¥230 per share dividend for FY2026, but Q1 FY2026 results (reported Feb 5, 2026) showed sales down 7.9% and operating income down 29% year-on-year, raising questions about whether full-year guidance of ¥65.0 billion sales will be met.

Timeline

2026-02-05Q1 FY2026 results: sales down 7.9% YoY to ¥15.466B, operating income down 29.0%
2025-11-18GR Japan industry report flags C-beauty and regulatory pressure on Japanese cosmetics sector
2025-11-07FY2025 results announced: net sales ¥64.72B (+1.4%), operating income ¥11.075B (-3.0%)
2025-11-07Management reorganization announced, including creation of new CTO-designated director role
2025-11-07FY2026 guidance issued: ¥65.0B sales, ¥11.4B operating income, ¥230/share dividend planned
2025-09-18Noevir Reset Serum launched with proprietary nirinsou botanical extract
2025-09-03Noevir 505 skincare line relaunched with new plant-extract and niacinamide formulations
2011Noevir Holdings incorporated as pure holding company in group reorganization
1964-04Noevir brand and group founded

Revision history

26 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

Estée Lauder LVMH Moet Hennessy Louis Vuitton Chow Sang Sang Holdings International Limited